Serenity Faces Skeptical Judge As IP Trial With Ferring Wraps
Law360 (July 23, 2020, 9:57 PM EDT) -- Drugmaker Serenity appears to be facing an uphill battle in its Zoom trial with rival Ferring over patents related to a nighttime urination medication, with the presiding New York federal judge telling Serenity during Thursday's closing arguments that it had "a problem."
The patent showdown being held remotely before Chief U.S. District Judge Colleen McMahon of the Southern District of New York concluded after roughly three weeks. Ferring Pharmaceuticals is seeking to invalidate two Serenity Pharmaceuticals patents relating to the use of the anti-diuretic compound desmopressin. Serenity has counterclaimed that Ferring's drug Nocdurna infringes those patents.
At Judge McMahon's behest, the...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!